Photo by Tambako, via Flickr
MONDAY, June 11 (HealthDay News) ? Perjeta (pertuzumab) has been approved by the U.S. Food and Drug Administration to treat people with HER2-positive late-stage breast cancer, the agency said in a news release.
HER2 is a protein involved in cell growth. Increased amounts of the protein, which tend to fuel cancer cell growth and survival, are found in about 20 percent of breast cancer cases, the FDA said.
Perjeta was approved for people who haven?t been previously treated with an anti-HER2 therapy for metastatic (spreading) breast cancer, the agency said.
via www.google.com by MedicineNet.com // Read More >>
winter classic 2012 georgia bulldogs football rashard mendenhall rachel zoe penn state football mt rainier national park rose parade
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.